Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Launched by ONE-CARBON THERAPEUTICS AB ·

Keywords

ClinConnect Summary

This clinical trial is testing a new medicine called TH9619 to see if it can help treat advanced cancers, including colorectal cancer, certain types of head and neck cancer, lung cancer, and stomach-related cancers. Since this is an early phase study, the main goal is to find the right dose of TH9619 that is safe and can be given to patients. This means the researchers are carefully increasing the dose to understand how much can be used without causing serious side effects.

People who might be eligible to join this study are adults between 65 and 74 years old who have one of these advanced cancers. Both men and women can participate. If you take part, you can expect to receive the study drug under close medical supervision at multiple centers. The doctors will monitor your health carefully to watch for any side effects and to see how your cancer responds to the treatment. This study is currently recruiting participants, so if you or a loved one fits these criteria and are interested, you can talk to your doctor about whether joining this trial might be an option.

Gender

ALL

Eligibility criteria